Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9) 9
index medicus (9) 9
clinical trials (6) 6
female (6) 6
aged (5) 5
male (5) 5
diabetes mellitus (4) 4
middle aged (4) 4
abridged index medicus (3) 3
adult (3) 3
atherosclerosis (3) 3
cardiac & cardiovascular systems (3) 3
cardiovascular disease (3) 3
cardiovascular diseases (3) 3
cerebral infarction (3) 3
clinical trials as topic (3) 3
diabetes (3) 3
medical research (3) 3
myocardial infarction (3) 3
patients (3) 3
randomization (3) 3
risk (3) 3
arteriosclerosis (2) 2
cardiovascular (2) 2
cardiovascular diseases - drug therapy (2) 2
cardiovascular diseases - prevention & control (2) 2
coronary vessels (2) 2
diabetes mellitus, type 2 - drug therapy (2) 2
disease (2) 2
disease control (2) 2
double-blind method (2) 2
drug administration schedule (2) 2
drug development (2) 2
drug dosages (2) 2
drug therapy, combination (2) 2
female reproduction (2) 2
glucagon (2) 2
glucagon-like peptide 1 (2) 2
heart attacks (2) 2
hemoglobin (2) 2
hypoglycemic agents - therapeutic use (2) 2
infarction (2) 2
insulin (2) 2
luteinizing hormone (2) 2
medicine (2) 2
medicine, experimental (2) 2
medicine, general & internal (2) 2
melatonin (2) 2
mellitus (2) 2
metabolism (2) 2
outcomes (2) 2
ovulatory cycle (2) 2
pancreatitis (2) 2
patient outcomes (2) 2
pharmacology & pharmacy (2) 2
portal blood (2) 2
rats (2) 2
research (2) 2
research design (2) 2
safety (2) 2
stroke (2) 2
trial (2) 2
type 2 diabetes (2) 2
1-alkyl-2-acetylglycerophosphocholine esterase - blood (1) 1
1-alkyl-2-acetylglycerophosphocholine esterase - metabolism (1) 1
1-deoxynojirimycin - administration & dosage (1) 1
1-deoxynojirimycin - adverse effects (1) 1
1-deoxynojirimycin - analogs & derivatives (1) 1
1-deoxynojirimycin - blood (1) 1
1-deoxynojirimycin - pharmacokinetics (1) 1
1102 cardiovascular medicine and haematology (1) 1
[ sdv.mhep ] life sciences [q-bio]/human health and pathology (1) 1
access to information (1) 1
acute cardiovascular problems (1) 1
acute coronary syndromes (1) 1
administration, oral (1) 1
adolescent (1) 1
adrenal (1) 1
aged, 80 and over (1) 1
aldosterone (1) 1
aldosterone - metabolism (1) 1
aldosterone blockade (1) 1
amiloride (1) 1
amiloride - pharmacology (1) 1
amiloride - therapeutic use (1) 1
analysis (1) 1
angina pectoris (1) 1
angiotensin-ii (1) 1
animals (1) 1
area under curve (1) 1
article (1) 1
aspirin (1) 1
aspirin - adverse effects (1) 1
aspirin - therapeutic use (1) 1
association (1) 1
association task-force (1) 1
atherosclerosis - complications (1) 1
atherosclerosis - drug therapy (1) 1
atrial-fibrillation (1) 1
benzaldehydes - pharmacology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
by Eikelboom, John W and Connolly, Stuart J and Bosch, Jackie and Dagenais, Gilles R and Hart, Robert G and Shestakovska, Olga and Diaz, Rafael and Alings, Marco and Lonn, Eva M and Anand, Sonia S and Widimsky, Petr and Hori, Masatsugu and Avezum, Alvaro and Piegas, Leopoldo S and Branch, Kelley R.H and Probstfield, Jeffrey and Bhatt, Deepak L and Zhu, Jun and Liang, Yan and Maggioni, Aldo P and Lopez-Jaramillo, Patricio and O’Donnell, Martin and Kakkar, Ajay K and Fox, Keith A.A and Parkhomenko, Alexander N and Ertl, Georg and Störk, Stefan and Keltai, Matyas and Ryden, Lars and Pogosova, Nana and Dans, Antonio L and Lanas, Fernando and Commerford, Patrick J and Torp-Pedersen, Christian and Guzik, Tomek J and Verhamme, Peter B and Vinereanu, Dragos and Kim, Jae-Hyung and Tonkin, Andrew M and Lewis, Basil S and Felix, Camilo and Yusoff, Khalid and Steg, P. Gabriel and Metsarinne, Kaj P and Cook Bruns, Nancy and Misselwitz, Frank and Chen, Edmond and Leong, Darryl and Yusuf, Salim and COMPASS Investigators
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events... 
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
by Hernandez, Adrian F and Green, Fiona and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Michael and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Rosenberg, Anne and Sigmon, Kristina and Sigmon, Kristina N and Somerville, Matthew and Somerville, Matthew C and Thorpe, Karl and Thorpe, Karl M and McMurray, John J V and McMurray, John J.V and Del Prato, Stefano and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Patel, Rajesh and Patel, Vickas and Patel, Prashant and Patel, Rajivkumar and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Harrison, Lindsay and Lopes, Renato and Mathews, Robin and Mehta, Anand and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Deb and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, John and Cooper, Lauren and Sharma, Abhinav and Sharma, Richa and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Wilson, Tim and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and James, Rachel and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Johnson, David and Johnson, Andrew and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Judith and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and ... and Harmony Outcomes Comm Investigator and Harmony Outcomes committees and investigators
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Medical services | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights